Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (CR) to treatment is infrequently reported. C...

詳細記述

保存先:
書誌詳細
出版年:Cancer Commun (Lond)
主要な著者: Brandi, Giovanni, Venturi, Michela, De Lorenzo, Stefania, Garuti, Francesca, Frega, Giorgio, Palloni, Andrea, Garajovà, Ingrid, Abbati, Francesca, Saccoccio, Gioconda, Golfieri, Rita, Pantaleo, Maria Abbondanza, Barbera, Maria Aurelia
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
Case Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6020209/
https://ncbi.nlm.nih.gov/pubmed/29941039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-018-0312-1
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料